People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Dfine Inc | — | Other | Series B | $77.3M | $290.6M | 2011 |
| Emboline Inc | — | Other | Series C | $66.9M | $795.9M | 2021 |
| Vascular Dynamics, Inc. | — | Other | Series B | $51.4M | $549.1M | 2020 |
| Elevian, Inc. | — | Other | Series B | $38.0M | $287.0M | 2021 |
| Velomedix, Inc. | — | Biotechnology | Series A | $27.3M | $335.9M | 2009 |
J. Casey McGlynn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside J. Casey McGlynn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Anderson | 1 | 24 |
| Daniel Burnett | 1 | 11 |
| Jonathan Silverstein | 1 | 10 |
| Russell Hirsch | 1 | 10 |
| Mark Allen | 1 | 9 |
| WILLIAM DAI | 1 | 8 |
| Csaba Truckai | 1 | 7 |
| Kevin Mosher | 1 | 6 |
| David Clapper | 1 | 6 |
| Robert Stern | 1 | 6 |
| Amir Belson | 1 | 6 |
| Andrew Cleeland | 1 | 5 |
| Brandon Simmons | 1 | 5 |
| Michael Henson | 1 | 5 |
| Brian Farley | 1 | 5 |
| John Dean | 1 | 5 |
| Nicholas Pappas | 1 | 4 |
| Thomas Thaler | 1 | 4 |
| Bryan Kim | 1 | 4 |
| Benjamin Tsai | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.